Adjuvant pembrolizumab beneficial in stage III melanoma

April 16, 2018

(HealthDay)—Pembrolizumab is associated with significantly longer recurrence-free survival than placebo as adjuvant therapy for high-risk stage III melanoma, according to a study published online April 15 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Association for Cancer Research, held from April 14 to 18 in Chicago.

Alexander M.M. Eggermont, M.D., Ph.D., from Gustave Roussy Cancer Campus Grand Paris, and colleagues randomized with completely resected stage III melanoma to receive 200 mg pembrolizumab (514 patients) or placebo (505 patients) intravenously every three weeks for 18 doses.

The researchers found that in the overall intention-to-treat population, pembrolizumab correlated with significantly longer recurrence-free survival than placebo at a median follow-up of 15 months (one-year rate of recurrence-free survival, 75.4 versus 61.0 percent; hazard ratio for recurrence or death, 0.57); the correlation was also seen in the subgroup of 853 patients with programmed death-1 ligand-positive tumors (one-year rate of recurrence-free survival, 77.1 versus 62.6 percent; hazard ratio, 0.54). Overall, 14.7 and 3.4 percent of patients in the pembrolizumab and placebo groups, respectively, had adverse events of grades 3 to 5 that were related to the trial regimen. One treatment-related death occurred in the pembrolizumab group.

"As for high-risk stage III melanoma, 200 mg of pembrolizumab administered every three weeks for up to one year resulted in significantly longer recurrence-free survival than , with no new toxic effects identified," the authors write.

One author disclosed financial ties to the pharmaceutical industry. The study was sponsored by Merck, the manufacturer of .

Explore further: ASCO: Pembrolizumab is good second-line Tx in urothelial CA

More information: Abstract/Full Text
More Information

Related Stories

ASCO: Pembrolizumab is good second-line Tx in urothelial CA

February 21, 2017
(HealthDay)—For patients with advanced urothelial cancer that has recurred or progressed after platinum-based chemotherapy, pembrolizumab is associated with increased overall survival, according to a study published online ...

Adjuvant Ipilimumab effects survival after high risk lymph node and melanoma resection

April 20, 2015
Results of an EORTC trial appearing in The Lancet Oncology show that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, ...

Combination therapy doubles survival in metastatic lung cancer

April 16, 2018
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to ...

New treatment for advanced melanoma shows promise

April 19, 2016
In a study appearing in the April 19, 2016 issue of JAMA, Antoni Ribas, M.D., Ph.D., of the University of California-Los Angeles, and colleagues examined tumor response and overall survival following administration of the ...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

October 8, 2016
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 ...

Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma

September 11, 2017
Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.